Pliant Therapeutics, Inc. — Form 8-K Summary
Filing date: June 8, 2023; reported event: Annual Meeting of Stockholders held June 7, 2023. As of the April 14, 2023 record date, 59,156,430 common shares were outstanding and entitled to vote.
Business Context and Reporting Period
The filing reports the results of the Company’s 2023 Annual Meeting of Stockholders. It does not provide operating or financial results for a reporting period.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other operating performance metrics. The filing text does not provide clear values for these items.
Meeting Results and Material Changes
| Proposal | Result | Vote Details |
|---|---|---|
| Election of Bernard Coulie, M.D., Ph.D. | Approved | 48,316,375 for; 1,094,357 withheld |
| Election of Gayle Crowell | Approved | 39,771,872 for; 9,638,860 withheld |
| Election of Suzanne Bruhn, Ph.D. | Approved | 39,735,738 for; 9,674,994 withheld |
| Named executive officer compensation | Approved by non-binding advisory vote | 47,994,590 for; 1,379,942 against; 36,200 abstain |
| Ratification of Deloitte & Touche LLP | Approved | 54,811,068 for; 12,512 against; 19,255 abstain |
All three Class III director nominees were elected to three-year terms ending at the 2026 Annual Meeting. Broker non-votes totaled 5,432,103 shares for Proposals 1 and 2. No other matters were submitted to or voted on.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance, business outlook, management commentary on operations, contingencies, or unusual financial items. Deloitte & Touche LLP’s appointment as independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified.
Investor Verification Points
- Verify the final composition and three-year terms of the Class III board members.
- Note that the executive compensation vote was advisory and non-binding.
- Confirm Deloitte & Touche LLP’s appointment for fiscal 2023.
- Review the Company’s Definitive Proxy Statement filed April 27, 2023 for proposal details and additional governance information.
- Use the Company’s periodic reports for financial performance, liquidity, cash runway, debt, development-program updates, and risk factors, which are not included in this filing.